A Phase 2 Study of Outpatient Epcoritamab as Second Line Therapy in Non-Transplant Eligible Relapsed/Refractory Large B-cell Lymphoma

This is a phase 2 study of outpatient administration of epcoritamab in non-transplant eligible large B-cell lymphoma that has relapsed after, or is refractory to, 1 prior line of therapy. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has approved epcoritamab as a treatment option for your disease after at least two prior treatments. The study treatment may continue for up to 24 cycles or un…